|
**Overview**: Ganglioside IgG Antibody Panel**Introduction**: The Ganglioside IgG Antibody Panel is a diagnostic tool designed to screen for neurological autoimmunity using serum samples. In India, anti-ganglioside IgG antibodies (GM1, GD1a, GD1b, GQ1b, GM2, GM3, GD2) are associated with Guillain-Barré syndrome (GBS) variants (~30-50 percent positivity in acute motor axonal neuropathy), Miller Fisher syndrome (GQ1b), multifocal motor neuropathy (GM1), and chronic inflammatory demyelinating polyneuropathy. High morbidity from under-testing in rural/low-SES patients with acute weakness or ophthalmoplegia, limited immunology labs, delayed IVIG/plasmapheresis leading to respiratory failure or permanent disability. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs immunoassay for multiple IgG specificities over 1-2 days with high specificity, valuable for confirming autoimmune neuropathy and guiding therapy. This diagnostic falls under autoimmune screening and targets patients with acute flaccid paralysis, ataxia, or neuropathy, addressing accurate detection to initiate immunotherapy promptly. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing neurological disability burden. Its serum-based approach ensures reliable antibody detection.**Other Names**: Ganglio IgG Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Ganglioside antibody panel standard; in India, used in GBS clinics.**Purpose**: The test screens for 7 parameters including GM1 IgG to guide neurological autoimmunity assessment, detect specific antibodies, inform immunotherapy.**Test Parameters**: 1. GM1 IgG, 2. GD1a IgG, 3. GD1b IgG, 4. GQ1b IgG, 5. GM2 IgG, 6. GM3 IgG, 7. GD2 IgG.**Pretest Condition**: No fasting required; patients should report weakness, ataxia, or recent infection.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptom onset, preceding infection, progression.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated autoimmune neuropathy including respiratory failure, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive specific IgG indicates autoimmune neuropathy variant, necessitating specialist input. Negative may require follow-up if clinical suspicion high.**Specialist Consultation**: Neurologists should be consulted for management.**Additional Supporting Tests**: Nerve conduction studies, anti-ganglioside IgM for confirmation.**Test Limitations**: May miss low-titer cases; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Neuropathy Studies India 2023. |
